{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-025050","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2026-06-12T18:20:32+00:00","discovered_at":"2026-06-12T18:21:00.609057+00:00","generated_at":"2026-06-12T18:21:09.449620+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ionis olezarsen OLE data: liver fat returns toward baseline after 24 months; 90%+ retention","bullets":["Mean hepatic fat fraction (HFF) levels returned toward baseline after 24 months of olezarsen 80 mg in CORE-OLE study of severe hypertriglyceridemia.","Patients transitioning from 50 mg to 80 mg showed less pronounced HFF changes; safety profile remained favorable with longer treatment.","Over 90% of eligible patients from CORE/CORE2 studies enrolled and remained in the open-label extension.","Data presented at National Lipid Association Scientific Sessions in Chicago on June 12, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-025050","json":"https://secwatch.observer/filing/0001140361-26-025050.json","markdown":"https://secwatch.observer/filing/0001140361-26-025050.md","text":"https://secwatch.observer/filing/0001140361-26-025050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036126025050/0001140361-26-025050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036126025050/ef20076110_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T18:21:09.449620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}